1. Report Industry Investment Rating No information about the industry investment rating is provided in the report. 2. Core Viewpoints of the Report - 2026 Q1 may see an increase in convertible bond calls, but high - parity convertible bond valuations are at historical highs. High valuations do not guarantee post - call valuation maintenance, and the pressure on convertible bond prices before and after the call is relatively large. It is recommended to take profit before the call or stop loss in a timely manner after the call based on market conditions [3][7]. - The overall trend of convertible bond valuations is likely to be high - level oscillations, with a possibility of short - term foaming. In January 2026, institutional demand for configuration will support valuations, and if the equity market performs better than expected, valuations may foam [28]. - In December 2025, the convertible bond market oscillated upward, with both convertible bonds and underlying stocks performing strongly, and valuations oscillated and increased. The trading volume of the convertible bond and equity markets decreased, but margin trading funds showed a strengthening trend [48][56]. - The issuance of new convertible bonds slightly increased in December 2025, and the number of new issuance plans continued to rise. The overall scale of holders in the Shanghai and Shenzhen Stock Exchanges decreased, with obvious reductions by insurance funds [3][62]. 3. Summary According to Relevant Catalogs 3.1 Historical Facts and Changes before and after Convertible Bond Calls - **Before the Call Announcement** - High market valuations do not guarantee post - call valuation maintenance. After the call, the valuation compresses to near 0%, and the compression process is basically completed before the call announcement [3][8]. - The strength of the underlying stock before the call can partially offset the compression of convertible bond valuations, but when valuations are high, the pressure on convertible bond prices before the call is still relatively large [3]. - The decline before the call mainly occurs within T - 10 days, and the day of the highest price is advancing [3][16]. - **After the Call Announcement** - In most months, convertible bond prices continue to decline after the call announcement, but in some months with a strong equity market, prices rebound [3][20]. - There is generally a decline of varying degrees on T - day, and the months with price rebounds mainly show strength from T + 1 to T + 15 days [3][21]. - The stronger the equity market, the more delayed the appearance of the highest price [3][25]. 3.2 Valuation Outlook - The overall trend is high - level oscillations, with a possibility of short - term foaming. In December 2025, valuations oscillated upward. As of December 31, 2025, the 100 - yuan par - value fitted conversion premium rate was 34.04%, up 2.50 pct from the end of November, reaching the highest level since 2019 [28]. 3.3 Key Focused Convertible Bonds - From December 1 to December 31, 2025, the convertible bond portfolio rose 3.84%, outperforming the benchmark index by 1.70 pct. Huayi and Xingqiu had obvious increases [41]. - The "Huachuang Convertible Bond" January key - focused portfolio is adjusted to include Xingqiu, Mingli, Yirui, Huachen, Huayi, Yifeng, Ziyin, Qingnong, Zhongyin, and Xingye [43]. 3.4 Market Review - **Market Performance** - In December 2025, the convertible bond market oscillated upward, with a strong performance in the second half of the month. Most sectors of the convertible bond market rose, and technology - related concepts declined. The science and technology and manufacturing sectors showed significant increases, and the cyclical sector also performed well [48][50]. - **Fund Performance** - The trading volume of the convertible bond and equity markets decreased slightly. From December 1 to December 31, 2025, the average daily trading volume of CSI Convertible Bonds was 63.803 billion yuan, a 1.27% decrease from November, and the average daily trading volume of Wind All - A was 1.880842 trillion yuan, a 1.76% decrease from November [56]. - Margin trading funds oscillated and strengthened. As of December 31, 2025, the balance of margin trading in the Shanghai and Shenzhen Stock Exchanges was approximately 2.53 trillion yuan, an increase of 66.664 billion yuan from the end of November. Most industries received net margin purchases [60]. 3.5 Supply and Demand Situation - **New Bond Issuance and Listing** - In December 2025, 7 convertible bonds were issued, with a total scale of 5.494 billion yuan, and 5 new convertible bonds were listed, with a total scale of 3.005 billion yuan. The online new - bond issuance subscription scale increased, with an average effective subscription amount of 8.85 trillion yuan, a 2.61% increase month - on - month [62]. - **Expected Issuance Scale and New Plans** - The total expected issuance scale is approximately 122.663 billion yuan. As of December 31, 2025, 7 listed companies obtained convertible bond issuance approvals, with a planned issuance scale of 8.583 billion yuan; 6 companies' convertible bond issuances passed the review committee, waiting for approvals, with a total scale of 3.361 billion yuan. In December, 6 new board plans were added, with a total scale of approximately 77.9 billion yuan [65]. - **Holder Scale Changes** - The overall scale of holders in the Shanghai and Shenzhen Stock Exchanges decreased. In December 2025, the total par value of convertible bonds held by the two exchanges was 552.692 billion yuan, a decrease of 6.144 billion yuan from November, a 1.10% decline. The scale of public funds increased, while the scale of enterprise annuities decreased [83][87].

Core Insights - The report highlights the performance of three investment strategies: Low Price Enhancement, Improved Dual Low, and High Price High Elasticity, which recorded returns of 0.2%, 2.3%, and 2.3% respectively during the last period, outperforming the benchmark return of 0.0% [1] - Year-to-date performance for these strategies shows returns of 17.4%, 29.4%, and 55.1%, with excess returns of 0.7%, 12.7%, and 38.4% compared to the benchmark return of 16.7% [1] Low Price Enhancement Strategy - Latest holdings include new entries such as Energy Convertible Bonds (Utilities), Hengyi Convertible Bonds (Petrochemicals), and others across various sectors [2] - The adjustment rationale for this strategy is based on a significant decline in the low-price index (down 0.6%), with a focus on selecting stable low-price varieties due to a relaxation of net profit constraints [3] Improved Dual Low Strategy - Latest holdings feature new entries like Changyin Convertible Bonds (Banking) and others from diverse sectors [4] - The adjustment rationale indicates a decline in the dual low index (down 0.5%), with a focus on stable performance and avoiding bonds in strong redemption progress [5] High Price High Elasticity Strategy - Latest holdings include new entries such as Yanggu Convertible Bonds (Basic Chemicals) and others from various industries [6] - The adjustment rationale reflects a 0.9% increase in the high-price index, with a focus on avoiding high-priced bonds facing strong redemption risks while maintaining industry diversification [7]

Core Viewpoint - The announcement from Yirui Biotechnology (300942.SZ) reveals plans for share reduction by its controlling shareholder and associated parties, indicating a potential liquidity event without significant impact on the company's governance or control structure [1][2]. Share Reduction Plan - Yirui (Hainan) Venture Capital Co., Ltd. plans to reduce its holdings by up to 11,521,758 shares, representing 2.84% of the total share capital, while associated entities plan to reduce their holdings by 288,500 shares (0.07%) and 341,800 shares (0.08%) respectively, totaling a maximum reduction of 12,152,058 shares or 3% of the total [1][2]. - The estimated cash proceeds from the planned share reduction amount to approximately 127.6 million yuan based on the last closing price of 10.50 yuan per share [1]. Current Shareholding Structure - As of the announcement date, Yirui Venture Capital holds 132,369,971 shares (32.68%), Yida Rui holds 19,008,003 shares (4.69%), and Yikai Rui holds 22,577,203 shares (5.57%) [2]. Previous Share Reduction Activities - Recent share reductions included Yirui Venture Capital selling 3,531,208 shares at an average price of 10.66 yuan per share, and the actual controller Zhu Hai reducing his holdings through various transactions, totaling approximately 125 million yuan from July to September 2025 [3]. Fundraising and Financial Performance - Yirui Biotechnology raised a total of 5.45 billion yuan from two fundraising events, with net profits for the years 2021 to 2024 showing fluctuations, including a loss of approximately 184.9 million yuan in 2023 [4][6].

Group 1 - The Zhongzheng Convertible Bond Index rose by 0.75% to 485.73 points on August 21 [1] - Notable gainers included Dongshi Convertible Bond, Shuiyang Convertible Bond, Dayuan Convertible Bond, Sailong Convertible Bond, and Yirui Convertible Bond, with increases of 20.00%, 11.18%, 9.89%, 8.02%, and 7.47% respectively [1] - Significant decliners included Chongda Convertible Bond 2, Jintian Convertible Bond, Jinlun Convertible Bond, Linuo Convertible Bond, and Borui Convertible Bond, with decreases of 6.55%, 5.42%, 4.50%, 3.74%, and 3.38% respectively [1]

Group 1 - The stock price of Yirui Bio is reported at 13.15 yuan, down 2.01% from the previous trading day, with an intraday high of 13.46 yuan and a low of 12.96 yuan, and a trading volume of 114 million yuan [1] - Yirui Bio's main business includes food rapid testing, animal epidemic disease testing, and in vitro diagnostics, with food rapid testing accounting for over 90% of its business [1] - The company is associated with sectors such as chemical pharmaceuticals, smallpox virus prevention, and specialized and innovative enterprises [1] Group 2 - On August 20, Yirui Bio announced that the board decided not to redeem the "Yirui Convertible Bonds" early, and if redemption clauses are triggered again within the next three months, the company will still not exercise its redemption rights [1] - On the same day, the net inflow of main funds was 4.467 million yuan, while the cumulative net outflow of main funds over the past five days was 10.4952 million yuan [1]

Core Viewpoint - The company, 易瑞生物, has decided not to exercise the early redemption rights for its convertible bonds, known as "易瑞转债," and will not redeem them in advance for the next three months [2] Summary by Sections - **Board Meeting Decision** - The third board meeting of the company was held on August 20, 2025, where the decision regarding the early redemption of "易瑞转债" was made [2] - **Redemption Terms** - The company will not exercise the early redemption rights for "易瑞转债" and will refrain from doing so even if the conditional redemption terms are triggered again within the next three months, from August 21, 2025, to November 20, 2025 [2] - **Future Considerations** - Starting from November 21, 2025, if the conditional redemption terms are triggered again, the board will convene to decide whether to exercise the early redemption rights [2]

Group 1 - The core viewpoint of the article highlights the significant financial performance of Muyuan Foods, reporting a net profit of 10.53 billion yuan in the first half of the year, representing a year-on-year increase of 1169.77% [1] - ST Zhongzhuang has received a court decision and appointed a restructuring manager, leading to the resumption of trading for its stocks and convertible bonds [1] - Several convertible bonds, including Yirui, Sailong, and Dongfeng, have announced that they will not be forcibly redeemed [1][2] Group 2 - The article provides a detailed table of convertible bonds, including their current prices, redemption prices, last trading dates, last conversion dates, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [4][6] - Specific convertible bonds such as Dayu, Puna, and Guanda are listed with their respective current prices and conversion values, indicating their market performance and potential investment opportunities [4][6]

Group 1 - The core point of the article is that Erye Biotechnology announced that its stock price has been above 130% of the conversion price of its convertible bonds for 10 consecutive trading days, which may trigger the conditional redemption clause of the bonds [1] - The conversion price of the "Erye Convertible Bonds" is set at 8.87 yuan per share, and the threshold for triggering the redemption is 11.531 yuan per share [1] - If the stock price continues to meet the criteria, the company's board of directors has the authority to decide whether to redeem all or part of the unconverted bonds at face value plus accrued interest [1]

Core Viewpoint - Shenzhen Yirui Biological Technology Co., Ltd. has issued convertible bonds with a total amount of RMB 328.2 million, and there are conditions under which these bonds may be redeemed if the stock price remains above a certain threshold [1][4]. Group 1: Convertible Bond Issuance - The company issued 3,281,967 convertible bonds at a face value of RMB 100 each, totaling RMB 328,196,700, with a term of 6 years [1]. - The convertible bonds were approved by the China Securities Regulatory Commission and began trading on September 6, 2023 [2]. Group 2: Conversion Terms - The conversion period for the bonds is from February 26, 2024, to August 17, 2029 [2]. - The initial conversion price was set at RMB 12.87 per share, which was later adjusted to RMB 8.89 per share on September 19, 2024, and subsequently to RMB 8.87 per share effective May 28, 2025 [3]. Group 3: Conditional Redemption Clause - The company has the right to redeem the bonds if the stock price reaches or exceeds 130% of the conversion price, which is RMB 11.531 per share [1][4]. - As of August 13, 2025, the stock price has met this condition for 10 trading days, indicating a potential for redemption [5].

Key Points - The company, Shenzhen Yirui Biological Technology Co., Ltd., has issued convertible bonds named "Yirui Convertible Bonds" with a face value of 1,000.00 yuan and an interest payment of 4.00 yuan (including tax) for every 10 bonds [1][5] - The convertible bonds were approved by the China Securities Regulatory Commission and were issued on August 18, 2023, with a term of 6 years [1][4] - The bonds are listed on the Shenzhen Stock Exchange and began trading on September 6, 2023 [4] - The coupon rates for the bonds are structured to increase over the years, starting from 0.20% in the first year to 2.00% in the sixth year [3][5] - Interest payments will be made annually, with the next payment scheduled for August 18, 2025, based on the interest rate of 0.40% for the second year [5][6] - The total issuance amount of the convertible bonds is 328.1967 million yuan, equivalent to 3,281,967 bonds [4] - The bonds are not secured and have been rated "A+" with a stable outlook by Zhongzheng Pengyuan Credit Rating Co., Ltd. [5][6] - Tax implications for interest income vary based on the type of bondholder, with individual investors subject to a 20% withholding tax, while qualified foreign institutional investors (QFII and RQFII) are exempt from corporate income tax and value-added tax [5][7]